-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Given -X- _ O
that -X- _ O
there -X- _ O
is -X- _ O
a -X- _ O
possibility -X- _ O
of -X- _ O
a -X- _ O
human -X- _ O
H5N1 -X- _ B-Patient
pandemic -X- _ O
and -X- _ O
the -X- _ O
fact -X- _ O
that -X- _ O
the -X- _ O
recent -X- _ O
H5N1 -X- _ B-Patient
viruses -X- _ I-Patient
are -X- _ O
resistant -X- _ O
to -X- _ O
the -X- _ O
anti-viral -X- _ O
drugs -X- _ O
, -X- _ O
newer -X- _ O
strategies -X- _ O
for -X- _ O
effective -X- _ O
therapy -X- _ O
are -X- _ O
warranted. -X- _ O
Previous -X- _ O
studies -X- _ O
show -X- _ O
that -X- _ O
single -X- _ O
mAbs -X- _ B-Intervention
in -X- _ O
immune -X- _ O
prophylaxis -X- _ O
can -X- _ O
be -X- _ O
protective -X- _ O
against -X- _ O
H5N1 -X- _ B-Patient
infection. -X- _ I-Patient
But -X- _ O
a -X- _ O
single -X- _ O
mAb -X- _ B-Intervention
may -X- _ O
not -X- _ O
be -X- _ O
effective -X- _ O
in -X- _ O
neutralization -X- _ O
of -X- _ O
a -X- _ O
broad -X- _ O
range -X- _ O
of -X- _ O
different -X- _ O
strains -X- _ O
of -X- _ O
H5N1 -X- _ B-Patient
and -X- _ O
control -X- _ O
of -X- _ O
potential -X- _ O
neutralization -X- _ O
escape -X- _ O
mutants. -X- _ O
METHODS -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
We -X- _ O
selected -X- _ O
two -X- _ B-Intervention
mAbs -X- _ I-Intervention
which -X- _ O
recognized -X- _ O
different -X- _ O
epitopes -X- _ O
on -X- _ O
the -X- _ O
hemagglutinin -X- _ O
molecule. -X- _ O
These -X- _ O
two -X- _ B-Intervention
mAbs -X- _ I-Intervention
could -X- _ I-Intervention
each -X- _ I-Intervention
neutralize -X- _ I-Intervention
in -X- _ I-Intervention
vitro -X- _ I-Intervention
escape -X- _ I-Intervention
mutants -X- _ I-Intervention
to -X- _ I-Intervention
the -X- _ I-Intervention
other -X- _ I-Intervention
and -X- _ I-Intervention
in -X- _ I-Intervention
combination -X- _ I-Intervention
could -X- _ I-Intervention
effectively -X- _ I-Intervention
neutralize -X- _ I-Intervention
viruses -X- _ I-Intervention
from -X- _ I-Intervention
clades -X- _ I-Intervention
0 -X- _ I-Intervention
, -X- _ I-Intervention
1 -X- _ I-Intervention
, -X- _ I-Intervention
2.1 -X- _ I-Intervention
, -X- _ I-Intervention
2.2 -X- _ I-Intervention
, -X- _ I-Intervention
2.3 -X- _ I-Intervention
, -X- _ I-Intervention
4 -X- _ I-Intervention
, -X- _ I-Intervention
7 -X- _ I-Intervention
and -X- _ I-Intervention
8 -X- _ I-Intervention
of -X- _ O
influenza -X- _ B-Patient
A -X- _ I-Patient
H5N1 -X- _ I-Patient
viruses. -X- _ I-Patient
This -X- _ O
combination -X- _ O
of -X- _ O
chimeric -X- _ B-Intervention
mAbs -X- _ I-Intervention
when -X- _ O
administered -X- _ O
passively -X- _ O
, -X- _ O
pre -X- _ O
or -X- _ O
post -X- _ O
challenge -X- _ O
with -X- _ O
10 -X- _ O
MLD50 -X- _ O
( -X- _ O
50 -X- _ O
% -X- _ O
mouse -X- _ O
lethal -X- _ O
dose -X- _ O
) -X- _ O
HPAI -X- _ B-Patient
H5N1 -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
viruses -X- _ I-Patient
could -X- _ O
protect -X- _ O
100 -X- _ O
% -X- _ O
of -X- _ O
the -X- _ O
mice -X- _ B-Patient
from -X- _ O
two -X- _ O
different -X- _ O
clades -X- _ O
of -X- _ O
viruses -X- _ O
( -X- _ O
clades -X- _ O
1 -X- _ O
and -X- _ O
2.1 -X- _ O
) -X- _ O
. -X- _ O
We -X- _ O
also -X- _ O
tested -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
a -X- _ O
single -X- _ B-Intervention
dose -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
combination -X- _ I-Intervention
of -X- _ I-Intervention
mAbs -X- _ I-Intervention
versus -X- _ I-Intervention
two -X- _ I-Intervention
doses. -X- _ I-Intervention
Two -X- _ B-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
combination -X- _ I-Outcome
therapy -X- _ I-Outcome
not -X- _ I-Outcome
only -X- _ I-Outcome
affected -X- _ I-Outcome
early -X- _ I-Outcome
clearance -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
but -X- _ I-Outcome
could -X- _ I-Outcome
completely -X- _ I-Outcome
prevent -X- _ I-Outcome
lung -X- _ I-Outcome
pathology -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
H5N1 -X- _ I-Outcome
infected -X- _ I-Outcome
mice. -X- _ I-Outcome
No -X- _ I-Outcome
escape -X- _ I-Outcome
variants -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
after -X- _ I-Outcome
therapy. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Our -X- _ O
studies -X- _ O
provide -X- _ O
proof -X- _ O
of -X- _ O
concept -X- _ O
that -X- _ O
the -X- _ O
synergistic -X- _ O
action -X- _ O
of -X- _ O
two -X- _ B-Outcome
or -X- _ I-Outcome
more -X- _ I-Outcome
mAbs -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
is -X- _ I-Outcome
required -X- _ I-Outcome
for -X- _ I-Outcome
preventing -X- _ I-Outcome
the -X- _ I-Outcome
generation -X- _ I-Outcome
of -X- _ I-Outcome
escape -X- _ I-Outcome
mutants -X- _ I-Outcome
and -X- _ I-Outcome
also -X- _ I-Outcome
to -X- _ I-Outcome
enhance -X- _ I-Outcome
the -X- _ I-Outcome
therapeutic -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
passive -X- _ I-Outcome
therapy -X- _ I-Outcome
against -X- _ I-Outcome
H5N1 -X- _ I-Outcome
infection. -X- _ I-Outcome
Combination -X- _ I-Outcome
therapy -X- _ I-Outcome
may -X- _ I-Outcome
allow -X- _ I-Outcome
for -X- _ I-Outcome
a -X- _ I-Outcome
lower -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
antibody -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
administered -X- _ I-Outcome
for -X- _ O
passive -X- _ O
therapy -X- _ O
of -X- _ O
influenza -X- _ O
infection -X- _ O
and -X- _ O
hence -X- _ O
can -X- _ O
be -X- _ O
made -X- _ O
available -X- _ O
at -X- _ O
reduced -X- _ O
economic -X- _ O
costs -X- _ O
during -X- _ O
an -X- _ O
outbreak -X- _ O
. -X- _ O

